HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.

AbstractBACKGROUND:
Anthracyclines are the first line antitumor agents against breast cancer, and P-glycoprotein (Pgp) is thought to be the main resistance mechanism against these agents. We have evaluated the chemosensitivity of fresh surgical specimens of breast cancer and compared them with their Pgp-expression.
MATERIALS AND METHODS:
The in vitro chemosensitivity of 65 surgical specimens obtained from 63 patients with advanced breast cancer was assessed by the histoculture drug response assay (HDRA) using doxorubicin (DXR), pirarubicin [(2"R)-4'-tetrahydropyranyladriamycin: THP], and epirubicin (EPIR). Breast cancer tissues were plated onto collagen gel matrix and incubated with 15 micrograms of DXR or EPIR, or 17 micrograms of THP per ml for 7 days with MTT assessed at the endpoint. The efficacy of the agents was evaluated by the inhibition index (I.I.) of the optical density detected by ELISA reader.
RESULTS:
When 60% or more I.I. was regarded as in vitro sensitive at each cut-off concentration of the drugs, the overall efficacy rates were 60.7%, 48.6%, and 78.6% for DXR, EPIR, and THP, respectively. Fifty-one surgical specimens were evaluated for the immunohistochemical analysis of Pgp and the correlation between the sensitivity to anthracyclines and the expression of Pgp was compared. Pgp was expressed in 23.5% (12/51) specimens and the efficacy of anthracyclines was reduced in Pgp-positive breast cancer tissues, although this reduction was low in THP with a statistically significant difference when comparing with DXR and EPIR.
CONCLUSION:
The present results suggest that THP might partly circumvent the mdr1/PgP-mediated drug resistance mechanism in human breast cancer tissue and would have some different antitumor spectra on breast cancer comparing with DXR and EPIR.
AuthorsT Kubota, T Furukawa, H Tanino, S Oura, H Murata, S Yuasa, K Morita, J Ueno, R Kozakai, T Yano
JournalAnticancer research (Anticancer Res) 1998 Mar-Apr Vol. 18 Issue 2A Pg. 967-72 ISSN: 0250-7005 [Print] Greece
PMID9615748 (Publication Type: Journal Article)
Chemical References
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antibiotics, Antineoplastic
  • Epirubicin
  • Doxorubicin
  • pirarubicin
Topics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (physiology)
  • Antibiotics, Antineoplastic (pharmacology)
  • Breast Neoplasms (drug therapy)
  • Doxorubicin (analogs & derivatives, pharmacology)
  • Drug Resistance, Neoplasm
  • Epirubicin (pharmacology)
  • Female
  • Humans
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: